EUCTR2006-005355-16-ES进行中（未招募）1 期
Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y multicéntrico para evaluar la eficacia y seguridad de dos dosis Ocrelizumab en pacientes con Lupus Eritematoso Sistémico Activo.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 423
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following criteria to be eligible for study entry. Documentation of each specific criterion must be present in the patient’s chart notes or records:
- •1. Age 16 years or above at the time of screening
- •2. Ability and willingness to provide written informed consent (or to obtain consent from a parent guardian where applicable) and to comply with the schedule of protocol requirements.
- •3. Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria. At least 4 criteria must be present, one of which must be a current positive ANA (titer at least 1:160).
- •4. Active disease at screening, as defined by the presence of EITHER a BILAG A score in at least one organ system domain other than the renal domain OR BILAG B scores in at least two organ system domains.
- •5. Background use of one of the following immunosuppressive drug for at least 60 days prior to Day 1 (AZA: 1-3 mg/kg/day, MMF: 1-3 g/day or MTX: 7.5-25 mg/week)
- •with a maximum change of no more than 50 mg of AZA daily, 500 mg MMF daily, or 5 mg MTX weekly in the 30 days prior to Day 1.
- •6. For patients of reproductive potential (males and females), a reliable means of contraception must be used for the duration of the study (e.g. hormonal contraceptive, intrauterine device, physical barrier) according to local guidelines and the treating physician’s recommendations. The relevant section of the product label for AZA, MMF or MTX (as appropriate) should be followed.
- •7. Female patients of childbearing potential must have a negative serum pregnancy test from the screening visit prior to enrollment at Day 1.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Related to SLE
- •1. Presence of active moderate to severe glomerulonephritis, as defined by proteinuria > 1 g/24 hr or urinary protein to urinary creatinine ratio (Upr:Ucr) > 1 and presence of either RBC casts or > 10 RBC/hpf (in the absence of infection or menstrual hematuria).
- •2. Currently active retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia.
- •Exclusions Related to General Health
- •3. Lack of peripheral venous access.
- •4. Pregnancy or breast feeding mothers.
- •5. History of severe allergic or anaphylactic reactions to humanized, chimeric or murine monoclonal antibodies or i.v. immunoglobulin.
- •6. Known severe chronic pulmonary disease (FEV1 < 50% predicted or functional dyspnea = Grade 3 on the MRC Dyspnea Scale).
- •7. Evidence of significant or uncontrolled concomitant diseases in any organ system not related to SLE (e.g. renal thrombosis, atherosclerotic cardiovascular disease, diabetes mellitus, accelerated hypertension, poorly controlled COPD or asthma, etc), which, in the investigator’s opinion, would impair patient participation.
- •8. Concomitant condition (e.g. asthma, Crohn’s disease, etc) which has required treatment with systemic corticosteroid (excluding topical or inhaled) at any time in the 52 weeks prior to screening.
- •9. Known HIV or chronic active Hepatitis B or chronic active Hepatitis C infection.
- •10. Known active infection of any kind (but excluding fungal infection of nail beds or oral thrush which has resolved before Day 1) within 30 days prior to Day. In addition, any major episode of infection requiring hospitalization or treatment with intravenous anti-infectives in the 30 days prior to Day 1 or oral anti-infectives in the 14 days prior to Day 1.
- •11. History of serious recurrent or chronic infection. A chest radiograph will be performed during screening, if not performed in the 12 weeks prior to screening, to assess infection. If there is any evidence of pulmonary infection a chest radiograph should be performed.
- •12. History of cancer, including solid tumors, hematological malignancies and carcinoma in situ (except basal cell carcinoma of the skin that has been excised and cured).
- •13. History of alcohol or drug abuse in the 52 weeks prior to screening.
- •14. Major surgery in the 4 weeks prior to screening excluding diagnostic surgery.
- •Exclusions Related to Medications
- •15. Previous treatment with CAMPATH-1H.
- •16. Previous treatment with a BAFF directed treatment (e.g. anti-BLyS) in the 12 months prior to screening.
- •17. Previous treatment with a B-cell targeted therapy other than one directed at BAFF (e.g. anti-CD20, anti-CD22).
- •18. Treatment with any investigational agent, other than those above, in the 28 days prior to screening or five half-lives of the investigational drug (whichever is longer).
- •19. Receipt of any live vaccine in the 6 weeks prior to Day 1 (it is recommended that a patient’s vaccination record and the need for immunization prior to receiving ocrelizumab should be carefully investigated).
- •20. Intolerance or contraindication to oral or i.v. corticosteroids.
- •21. Treatment with a second immunosuppressive or immunomodulatory drug (e.g., sulfasalazine, dapsone) in the 8 weeks prior to Day 1 (12 weeks prior to Day 1 for
- •leflunomide or 4 weeks prior to Day 1 after 11 days of standard cholestyramine or activated charcoal drug removal).
- •22. Prednisone dose of = 0.7 mg/kg/day (or equivalent) for
研究者
相似试验
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos con una dosis de 10 mg de vardenafilo dos veces al día para evaluar el efecto en la prueba urodinámica en pacientes con vejiga hiperactiva (hiperactividad del detrusor) Randomized, double-blind, placebo-controlled, parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity).Vejiga hiperactiva (hiperactividad del detrusor) Overactive bladder (detrusor overactivity)MedDRA version: 9.1 Level: LLT Classification code 10059617 Term: Overactive bladderEUCTR2006-005145-11-ESBayer Healthcare AG
进行中（未招募）
不适用
Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, adaptativo, multicéntrico de 12 semanas de duración para evaluar la eficacia y seguridad de cinco dosis de LCQ908 (2, 5, 10, 15 y 20 mg) o 100 mg de sitagliptina para el control de la glucemia en pacientes obsesos con diabetes tipo 2 tratados con metforminaEUCTR2009-009888-60-ESovartis Farmacéutica S.A.720
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico, fase II de atacicept en pacientes con artritis reumatoide moderada a gravemente activa, sin tratamiento previo con anti-TNFa y con respuesta insuficiente a metrotexato.A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti-TNFa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate. - Atacicept en pacientes con AR sin tratamiento previo con anti-TNFaEUCTR2007-002536-29-ESMerck Serono International
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, controlado con placebo para investigar la eficacia de vardenafilo a dosis flexible en sujetos con disfunción eréctil y en la calidad de la vida sexual de sus parejas. Estudio PARTNER II - PARTNER IIEUCTR2006-001228-37-ESBayer HealthCare AG, D-51368 Leverkusen
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y de grupos paralelos de un año de duración, seguido de 2 años de tratamiento abierto para determinar la seguridad y eficacia de Risedronato diario 2,5 mg o 5,0 mg administrado oralmente en niños ³ 4 a < 16 años con osteogénesis imperfecta. - POISEOsteogenesis ImperfectaEUCTR2004-000485-13-ESProcter & Gamble Ltd124